20S Proteasome α8 inhibitors belong to a class of chemical compounds specifically designed to target and modulate the activity of the α8 subunit of the 20S proteasome complex. The 20S proteasome is a large, barrel-shaped protein complex found in eukaryotic cells and plays a central role in the degradation of intracellular proteins. It consists of four stacked rings, with the two outer rings composed of α subunits and the two inner rings composed of β subunits. The α8 subunit is one of the α subunits in the outer ring of the 20S proteasome, and it is involved in the regulation of the proteasome's catalytic activity. Inhibitors targeting α8 are used in molecular and cellular biology research to investigate the specific functions and regulatory mechanisms associated with this subunit.
The development of 20S Proteasome α8 inhibitors involves a combination of biochemical and structural approaches to identify molecules that can selectively bind to the α8 subunit and modulate its activity. By inhibiting the α8 subunit, these compounds can impact the proteolytic activity of the 20S proteasome complex, affecting the degradation of specific target proteins within the cell. This class of inhibitors enables researchers to explore the intricate roles played by the α8 subunit in protein degradation pathways and cellular homeostasis. Furthermore, these inhibitors are valuable tools for dissecting the broader network of cellular processes that rely on the proper functioning of the 20S proteasome complex, contributing to our understanding of fundamental cell biology mechanisms and providing insights into avenues for further scientific inquiry.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that could indirectly decrease α8 subunit expression by causing a feedback inhibition of proteasome gene expression due to protein buildup. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
An irreversible proteasome inhibitor that may result in the downregulation of the α8 subunit's expression due to cellular responses to proteasome inhibition. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
Targets the proteasome and could potentially alter the transcription of proteasome-related genes, including those for the α8 subunit. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
May downregulate proteasome subunit expression as a part of the cellular response to proteasome inhibition. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
By inhibiting the proteasome, it might reduce α8 subunit expression through feedback mechanisms regulating proteasome subunit levels. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
A specific inhibitor of the proteasome that could lead to changes in the expression of proteasome subunits, including α8, as a stress response. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
As a proteasome inhibitor, it might trigger a cellular response that alters the transcription or stability of mRNA encoding the α8 subunit. | ||||||
Delanzomib, free base | 847499-27-8 | sc-396774 sc-396774A | 5 mg 10 mg | $160.00 $300.00 | ||
Could potentially lead to a decrease in α8 expression by disrupting proteasomal degradation pathways and triggering cellular stress responses. | ||||||